{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:21:41Z","timestamp":1773861701322,"version":"3.50.1"},"reference-count":38,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"DOI":"10.1182\/bloodadvances.2025017795","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T15:49:36Z","timestamp":1766591376000},"page":"1469-1472","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["A proposal for expedited stem cell transplantation for\n                    <i>TP53<\/i>\n                    -mutant myelodysplastic neoplasms and acute myeloid leukemia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-1902","authenticated-orcid":false,"given":"Shyam A.","family":"Patel","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA"},{"name":"2Center for Clinical and Translational Science, UMass Chan Medical School, Worcester, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-759X","authenticated-orcid":false,"given":"Steven M.","family":"Devine","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6602-5505","authenticated-orcid":false,"given":"Jan","family":"Cerny","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA"},{"name":"2Center for Clinical and Translational Science, UMass Chan Medical School, Worcester, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"7","key":"2026031808014981800_bib1","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"23","key":"2026031808014981800_bib2","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2026031808014981800_bib3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"2026031808014981800_bib4","doi-asserted-by":"crossref","first-page":"E232","DOI":"10.1002\/ajh.26546","article-title":"Outcomes of TP53-mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival","volume":"97","author":"Badar","year":"2022","journal-title":"Am J Hematol"},{"issue":"25","key":"2026031808014981800_bib5","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","article-title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation","volume":"32","author":"Bejar","year":"2014","journal-title":"J Clin Oncol"},{"issue":"26","key":"2026031808014981800_bib6","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood-2018-02-832360","article-title":"Prognostic factors influencing survival after allogeneic transplantation for AML\/MDS patients with TP53 mutations","volume":"131","author":"Ciurea","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2026031808014981800_bib7","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1080\/10428194.2020.1759051","article-title":"Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience","volume":"61","author":"Bewersdorf","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"2026031808014981800_bib8","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","article-title":"Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv"},{"issue":"28","key":"2026031808014981800_bib9","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1200\/JCO.23.00866","article-title":"Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the blood and marrow transplant clinical trials network 1102 study","volume":"41","author":"Versluis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026031808014981800_bib10","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"issue":"15","key":"2026031808014981800_bib11","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/cncr.34268","article-title":"Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia","volume":"128","author":"Loke","year":"2022","journal-title":"Cancer"},{"issue":"11","key":"2026031808014981800_bib12","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1182\/bloodadvances.2024014499","article-title":"TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS\/AML for transplantation","volume":"9","author":"Lontos","year":"2025","journal-title":"Blood Adv"},{"issue":"18","key":"2026031808014981800_bib13","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"2026031808014981800_bib14","first-page":"S2666","article-title":"Allogeneic hematopoietic cell donor selection: contemporary guidelines from the NMDP\/CIBMTR","volume":"31","author":"Jimenez Jimenez","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"suppl 1","key":"2026031808014981800_bib15","doi-asserted-by":"crossref","first-page":"7591","DOI":"10.1182\/blood-2022-162581","article-title":"Access: a multi-center, phase II trial of HLA-mismatched unrelated donor hematopoietic cell transplantation with post-transplantation cyclophosphamide for patients with hematologic malignancies","volume":"140","author":"Al Malki","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2026031808014981800_bib16","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1182\/bloodadvances.2024015173","article-title":"Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial","volume":"9","author":"Raiola","year":"2025","journal-title":"Blood Adv"},{"issue":"24","key":"2026031808014981800_bib17","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood.2023023697","article-title":"Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT","volume":"143","author":"Sanz","year":"2024","journal-title":"Blood"},{"issue":"13","key":"2026031808014981800_bib18","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2026031808014981800_bib19","first-page":"S63","article-title":"Final results from BMT CTN 1702 \u2013 no difference in survival or other transplant outcomes based on donor search prognosis","volume":"31","author":"Lee","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"24","key":"2026031808014981800_bib20","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1182\/blood.2021014520","article-title":"Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML","volume":"139","author":"Murdock","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2026031808014981800_bib21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41375-023-02119-0","article-title":"Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission","volume":"38","author":"Yanada","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"2026031808014981800_bib22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41409-024-02486-x","article-title":"Better pre-transplant treatment options for TP53-mutated MDS: cytoreductive or non-cytoreductive therapy?","volume":"60","author":"Jiang","year":"2025","journal-title":"Bone Marrow Transpl"},{"key":"2026031808014981800_bib23","doi-asserted-by":"crossref","first-page":"e830","DOI":"10.1016\/S2352-3026(24)00241-2","article-title":"Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"issue":"24","key":"2026031808014981800_bib24","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"26","key":"2026031808014981800_bib25","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026031808014981800_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-022-01361-w","article-title":"Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk\/secondary AML: post hoc analysis of a randomized, phase 3 trial","volume":"15","author":"Cortes","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"31","key":"2026031808014981800_bib27","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning","volume":"32","author":"Kanakry","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026031808014981800_bib28","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","article-title":"Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation","volume":"127","author":"Mielcarek","year":"2016","journal-title":"Blood"},{"issue":"28","key":"2026031808014981800_bib29","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.24.00184","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors","volume":"42","author":"Shaffer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026031808014981800_bib30","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"issue":"34","key":"2026031808014981800_bib31","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J Clin Oncol"},{"issue":"21","key":"2026031808014981800_bib32","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026031808014981800_bib33","first-page":"4952.1.1","article-title":"MO-TRANS: a randomized, double-blind, placebo-controlled, multi-center phase III study of mocravimod (MOC) as adjunctive and maintenance treatment in AML patients undergoing allogeneic hematopoietic cell transplantation","volume":"144","author":"Sanchez-Petitto","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026031808014981800_bib34","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00277-019-03636-8","article-title":"Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia","volume":"98","author":"Gao","year":"2019","journal-title":"Ann Hematol"},{"issue":"36","key":"2026031808014981800_bib35","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026031808014981800_bib36","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/S2352-3026(22)00375-1","article-title":"The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial","volume":"10","author":"Xuan","year":"2023","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2026031808014981800_bib37","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2024-203903","article-title":"Measurable residual disease monitoring by duplex sequencing for TP53 in the post allogeneic stem cell transplantation study with eprenetapopt (APR-246) + azacitidine strongly predicts outcomes","volume":"144","author":"Sallman","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2026031808014981800_bib38","first-page":"885","article-title":"Blood and marrow transplant clinical trials network state of the science symposium 2021: looking forward as the network celebrates its 20th year","volume":"27","author":"Heslop","year":"2021","journal-title":"Transpl Cell Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1469\/2505456\/blooda_adv-2025-017795-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1469\/2505456\/blooda_adv-2025-017795-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:02:03Z","timestamp":1773835323000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1469\/557471\/A-proposal-for-expedited-stem-cell-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017795","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,2,25]]}}}